CY1114254T1 - Intravenous injection of non-neurotoxic plasminogen activators to treat cerebral episode - Google Patents

Intravenous injection of non-neurotoxic plasminogen activators to treat cerebral episode

Info

Publication number
CY1114254T1
CY1114254T1 CY20131100248T CY131100248T CY1114254T1 CY 1114254 T1 CY1114254 T1 CY 1114254T1 CY 20131100248 T CY20131100248 T CY 20131100248T CY 131100248 T CY131100248 T CY 131100248T CY 1114254 T1 CY1114254 T1 CY 1114254T1
Authority
CY
Cyprus
Prior art keywords
intravenous injection
plasminogen activators
treat cerebral
neurotoxic plasminogen
episode
Prior art date
Application number
CY20131100248T
Other languages
Greek (el)
Inventor
Mariola Söhngen
Wolfgang Söhngen
Wolf-Dieter Schleuning
Robert Medcalf
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04730516A external-priority patent/EP1622639B1/en
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of CY1114254T1 publication Critical patent/CY1114254T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η εφεύρεση αφορά τη χρήση μη νευροτοξικών παραγόντων ενεργοποίησης του πλασμινογόνου, παραδείγματος χάριν από Desmodus rotundus (DSPA) ή γενετικά τροποποιημένων παραγόντων ενεργοποίησης του πλασμινογόνου, ιδιαιτέρως ανθρώπινης προέλευσης, για την παραγωγή ενός ενέσιμου φαρμάκου για τη θεραπευτική αντιμετώπιση του εγκεφαλικού επεισοδίου σε ανθρώπους.The invention relates to the use of non-neurotoxic plasminogen activating agents, for example Desmodus rotundus (DSPA) or genetically modified plasminogen activating agents, particularly of human origin, for the production of a human injectable drug for its treatment.

CY20131100248T 2003-05-02 2013-03-26 Intravenous injection of non-neurotoxic plasminogen activators to treat cerebral episode CY1114254T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2003/004608 2003-05-02
PCT/EP2003/004729 WO2004096267A1 (en) 2003-05-02 2003-05-06 Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
EP04730516A EP1622639B1 (en) 2003-05-02 2004-04-30 Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke

Publications (1)

Publication Number Publication Date
CY1114254T1 true CY1114254T1 (en) 2016-08-31

Family

ID=33395696

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100248T CY1114254T1 (en) 2003-05-02 2013-03-26 Intravenous injection of non-neurotoxic plasminogen activators to treat cerebral episode

Country Status (14)

Country Link
JP (1) JP2012077090A (en)
CN (1) CN1849133B (en)
AU (3) AU2003227721A1 (en)
CY (1) CY1114254T1 (en)
DK (1) DK1622639T3 (en)
EA (2) EA201000501A1 (en)
ES (1) ES2401782T3 (en)
HK (1) HK1092045A1 (en)
IL (1) IL171636A (en)
MY (1) MY151447A (en)
PT (1) PT1622639E (en)
SI (1) SI1622639T1 (en)
WO (1) WO2004096267A1 (en)
ZA (2) ZA200703704B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (en) 2001-11-02 2003-05-22 Paion Gmbh DSPA for the treatment of stroke
TWI445540B (en) 2007-04-20 2014-07-21 Ajinomoto Kk Anti-hypothermia composition
EP2014296A1 (en) * 2007-07-10 2009-01-14 PAION Deutschland GmbH Novel strategies for increasing the reperfusion in obstructed blood vessel
AR067345A1 (en) * 2007-07-10 2009-10-07 Paion Deutschland Gmbh USE OF THROMBOMODULIN FOR THE PREPARATION OF A THROMBOLITIC MEDICINAL PRODUCT

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE69054B1 (en) * 1988-07-20 1996-08-07 Schering Ag Vampire bat salivary plasminogen activators
NL8902454A (en) * 1989-10-03 1991-05-01 Stichting Centraal Lab MUTANTS OF THE HUMANE PLASMINOGENIC ACTIVATOR INHIBITOR 1 (PAI-1), THEIR PREPARATION AND USE, AND RECOMBINANT POLYNUCLEOTIDES INCLUDING GENETIC INFORMATION CODING FOR THESE MUTANTS.
DK0530937T3 (en) * 1991-09-05 1999-05-10 Schering Ag Inhibitor with collagen-induced platelet aggregation
DE10153601A1 (en) * 2001-11-02 2003-05-22 Paion Gmbh DSPA for the treatment of stroke

Also Published As

Publication number Publication date
WO2004096267A1 (en) 2004-11-11
ES2401782T3 (en) 2013-04-24
JP2012077090A (en) 2012-04-19
MY151447A (en) 2014-05-30
PT1622639E (en) 2013-04-01
SI1622639T1 (en) 2013-05-31
CN1849133A (en) 2006-10-18
CN1849133B (en) 2011-03-30
IL171636A (en) 2013-07-31
DK1622639T3 (en) 2013-04-15
AU2004233601B2 (en) 2009-11-26
ZA200509053B (en) 2007-11-28
EA201000501A1 (en) 2010-10-29
HK1092045A1 (en) 2007-02-02
AU2003227721A1 (en) 2004-11-23
AU2004233601A1 (en) 2004-11-11
ZA200703704B (en) 2008-08-27
EA200501733A1 (en) 2006-06-30
AU2010200718A1 (en) 2010-03-18
EA013837B1 (en) 2010-08-30

Similar Documents

Publication Publication Date Title
HRP20050903A2 (en) Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
NL301089I2 (en) imlifidase
CY1109648T1 (en) NON-NEUROTOTOXIC PLASMINOGEN ACTIVATORS FACTORS FOR BRAIN INTERVENTION
CY1121877T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PIMOBENDANE
CY1119723T1 (en) PHARMACEUTICAL FORMS OF PEPTILE CONTENTS OF PROPYLENGYLIC THAT ARE OPTIMAL FOR PRODUCTION AND USE IN APPLIANCES
CY1110835T1 (en) DIFFINYL PRODUCTS AND THEIR USE IN THE TREATMENT OF USITIS C
ATE502633T1 (en) CYCLOSPORINS FOR THE TREATMENT AND PREVENTION OF EYE DISEASES
DK1505990T3 (en) Methods for the treatment of hepatitis
EA200802213A1 (en) METHODS OF TREATING BLOOD DISEASES
CY1113766T1 (en) INDOLIDONES PRODUCTS FOR THE TREATMENT OR PREVENTION OF DISEASES
ATE297922T1 (en) ISOINDOLIN-1-ONE AS GLUCOCINASE ACTIVATORS
CY1110889T1 (en) C-ARYLIC GLUCOSYSTEMS SGLT2 INSPECTIONS AND METHOD FOR PRODUCTION
UY26885A1 (en) TETRAZOLIL-PHENYL ACETAMIDO GLUCOQUINASA ACTIVATORS
UY28885A1 (en) 4-PHENYLAMINE-QUINAZOLIN-6-IL-AMIDAS CROSSED REFERENCE ON RELATED APPLICATION (S)
EA200600203A1 (en) DERIVATIVES 2- (CHINOXALIN-5-ILSULPHONYLAMINO) BENZAMIDE IN THE QUALITY OF CCK2 MODULATORS
CY1108843T1 (en) 3,11B CIS DIMRODETRETRAVENASINE FOR THE TREATMENT OF SCHIZOPHRENIA AND OTHER PSYCHOLOGIES
EA200700717A1 (en) СУЛЬФОНАМИНЫ
NO20054494L (en) Peptidvektorer
CY1114254T1 (en) Intravenous injection of non-neurotoxic plasminogen activators to treat cerebral episode
DOP2006000233A (en) KINASE INHIBITORS
NO20025405D0 (en) Modulators for TNF-alpha signaling
CY1105317T1 (en) USE OF 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXANE SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF URINARY INCONTINENCE
CY1105142T1 (en) USE OF 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXANE SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF URINARY INCONTINENCE
EA200100930A1 (en) METHOD OF TREATMENT COPD
ATE402694T1 (en) USE OF 1-PHENYL-3-DIMETHYLAMINO-PROPANE COMPOUNDS FOR THE THERAPY OF URINARY INCONTINENCE